METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
Carcinoma stomach presentation
1.
2.
3.
4.
5.
6. 2nd leading cause of cancer related death after lung cancer.
The highest incidences are found in East Asia (Japan and China)>
South America > Eastern Europe
RISK FACTORS
ACQUIRED FACTORS
H. Pylori infection ( 3-6 times)- distal gastric cancer and
intestinal type
High intake of smoked and salted foods
Nitrates
Diet low in fruits and vegetables
Smoking
Obesity proximal gastric lesions
Barrett esophagus/GERD
Prior subtotal gastrectomy (25%)
RT exposure
7. GENETIC FACTORS
E- cadherin (CDH-1 gene)
Type A blood group
Pernicious anemia (5-10%)
HNPCC
Li-Fraumeni syndrome
10. Type I, nodular polypoid tumor without
ulceration and usually with a broad
base;
Type II- fungating, exophytic,
circumscribed tumor with defined
sharp margins, devoid of ulceration
except at its dome
Type III- ulcerating tumor +
penetrating, infiltrating ulcer base;
Type IV - diffuse thickening of the
gastric wall with no discretely
marginated mass or ulceration,leather
bottle,linitis plastica
Type v - unabler to classify
11. 4 groups
Well differentiated (1) to anaplastic (4)
12. Intestinal Diffuse
Environmental
Gastric atrophy and
intestinal metaplasia
M>F
Increase incidence with
age
Gland formation
Haematogenous spread
Epidemic
Distal part of stopmach
Familial
Blood group A
F>M
Younger age
Poorly differentiated
signet ring cells
Transmural/lymphatic
Endemic
Proximal part of stomach
13. Abdominal discomfort
weight loss
Loss of appetite
Early satiety
Nausea and vomiting
Black Tarry stool
Duration of symptom is <3 months in almost 40% of patients
and > 1 year in 20%.
PHYSICAL EXAMINATION
Can reveal advanced disease
- Abdominal mass
-Epigastric or liver mass, periumbilical node (Sister Mary
Joseph node)
- Palpable left supraclavicular node (Virchow’s node)
- Rectal shelf (Blumer’s shelf)
- Left axilla lymphnode (Irish nodes)
14. TEST
ENDOSCOP
Y
Direct visualization /cytology. Biopsy usual in 90% cases
But linitis plastica & small<3 cm & cardia lesion is difficult to diagnose
DOUBLE
CONTRAST
STUDY
: small lesion limited to inner layer of stomach wall.
CECT SCAN: For both extent of spread & radiation portal (abdomen)
Mediastinal LN ( in case of distal esophageal junction and thoracic
mets.)
HELICAL
CT:
More useful In detection of smaller LN
LAPAROSC
OPIC
STUDY:
Helps in detection in metastatic disease in case of operable lesion in
preoperative imaging. Peritoneal fluid should be sampled in case of
+ve is considered as M1 disease.
• T staging is accurate enough in 86 % case by EUS. Whereas 43% by CT.
• EUS is 1st line imaging modality in T category
• Diffuse /mucinous tumors – pet has lower detection rate. As FDG accumulation is
lower in this cases
15. AJCC – TNM staging
Japanese gastric cancer staging
Staging for E G junction cancer
17. Regional Lymph Nodes (N)*
N1 Metastasis in 1-2 regional lymph nodes
N2 Metastasis in 3-6 regional lymph nodes
N3 Metastasis in 7 or more regional lymph nodes
N3a Metastasis in 7-15 regional lymph nodes
N3b Metastasis in 16 or more regional lymph nodes
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
18.
19.
20.
21. Correction of anemia
Correction of nutritional status
Fluid and electrolytes
Cardiac, respiratory and renal status
Adequate blood
Pre operative stomach wash
Prophylactic antibiotics
23. Early gastric cancer
Tumor less than 2cm
Elevated well differentiated tumors
Without nodal involvement
Tumour less than 1cm in diffuse
lesion
28. SURGERY
Primary treatment of gastric cancer
OPTIONS-
Radical Total Gastrectomy –
Diffuse involvement
Proximal involvement.
Radical Subtotal Gastrectomy –
Distal cancers,
Equivalent survival
Lesser complications
In proximal cancer, total
gastrectomy is not necessary when
subtotal gastrectomy will provide a
5 cm clearance of the gross tumour.
29. • Ligation of left and
right gastric and
gastro epiploic arteries
• En bloc removal of
75% of stomach
• Pylorus
• 2cm of duodenum
• Greater and lesser
omentum
• All associated
lymphatic tissue
35. • Adherent to pancreas or colon or mesocolon
• Ascites
• Para-aortic lymph nodes
• Secondaries in liver
• Palpable mass is incurable but can be resectable
surgically
• Blumer shelf
• Left supraclavicular nodes
• Sister Mary Joseph nodule
• Irish node (Left axillary lymph node secon daries)
36. Lymphadenectomy:
1. Adequate staging
2.Adequate therapy
At least 15 LN need to be retrieved.
Total gastrectomy
D0: Lymphadenectomy less than
D1
D1: Nos. 1–7
D1+:D1, Nos. 8a, 9, 11p
D2: D1+Nos. 8a, 9, 10, 11p, 11d,
12a.
Distal gastrectomy
D0: Lymphadenectomy less than
D1
D1: Nos. 1, 3, 4sb, 4d, 5, 6, 7
D1+:D1,Nos. 8a, 9
D2: D1+Nos. 8a, 9, 11p, 12a.
Japanese gastric cancer treatment guidelines 2010
37. Pylorus-preserving gastrectomy
D0: Lymphadenectomy less than
D1
D1: Nos. 1, 3, 4sb, 4d, 6, 7
D1+:D1,Nos. 8a, 9.
Proximal gastrectomy
D0: Lymphadenectomy less than D1
D1: Nos. 1, 2, 3a, 4sa, 4sb, 7
D1+:D1,Nos. 8a, 9, 11p
Japanese gastric cancer treatment guidelines 2010
38. Type Descriptions
D1 lymphadenectomy T1a tumors that do not meet the criteria for
EMR
cT1bN0 tumors that are differentiated type
and <1.5 cm
D1+lymphadenectomy cT1N0 tumors other than the above
D2 lymphadenectomy potentially curable T2-T4 tumors, &
cT1N+tumors.
complete clearance of No. 10 nodes by
splenectomy should be considered for
potentially curable T2-T4 tumors invading the
greater curvature of the upper stomach.
D2+lymphadenectomy Non standard
prophylactic para-aortic lymphadenectomy
Denied by jcog 9501
prognosis of this population is poor.
Japanese gastric cancer treatment guidelines 2010
A recent meta-analysisof 12 randomised, controlled trials (RCTs) confirmed
no overall
survival (OS) benefit for D2 lymphadenectomy, although a benefit was seen
among patients who had resection without a splenectomy and/or
pancreatectomy
39. Gastric cancer responds well to
combination cytotoxic
chemotherapy
Neo adjuvant therapy improves
outcome
First line treatment in inoperable
disease
Palliative in advanced disease
Trantuzumab – in HER2 positive
gastric cancer
40. Down staging of disease --- increase
resectability
Determine sensitivity to chemotherapy
Decreases micro-metastatic burden
Epirubicin + cis-platinum+ infusional
5-FU/ capecitabine
41. Post op XRT
Pre op XRT
Intraoperative RT
Palliative RT
Indications-
T3-4 resectable disease
Margins positive
Residual disease
LN +ve disease
Inoperable
42. Idealized portals from patterns of failure data need
modification individually for patient's initial extent of disease.
Gastric/tumor bed, anastomosis and gastric remnant, and
regional lymphatics should be included in most patients.
Major nodal chains at risk include
lesser and greater curvature;
celiac axis;
pancreaticoduodenal,
splenic,
suprapancreatic,
porta hepatis groups;
para-aortics to the level of L3.
Any tumor originating in the stomach has a high propensity of spread to
nodes along the greater and lesser curvature, although they are most
likely to spread to those sites in close anatomic proximity to the primary
tumor mass.